Practical Considerations in Managing Relapsed Multiple Myeloma

Considerable advances have been made in the treatment of relapsed and relapsed/refractory multiple myeloma (RRMM), with numerous novel agents and combination strategies receiving regulatory approvals worldwide over the last several years. An increasing body of phase III data clearly demonstrates increased overall response rates, improved depths of response and more durable responses when a third novel agent is incorporated into Lenalidomide-Dexamethasone and Bortezomib-Dexamethasone platforms, in most cases with acceptable toxicity.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 21, 2016 Category: Hematology Authors: Amit Agarwal, Eric Chow, Manisha Bhutani, Peter M. Voorhees, Reed Friend, Saad. Z. Usmani Tags: Review Article Source Type: research